Cost-Effectiveness of Dexamethasone Intravitreal Implant in Naïve and Previously Treated Patients with Diabetic Macular Edema
International Journal of Environmental Research and Public Health · 2023
DOI: 10.3390/ijerph20085462 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Marta Medina-Baena und 3 weiteren Autor:innen. Beteiligte Einrichtung: Puerta del Mar University Hospital, 11009 Cadiz, Spain. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Diabetes Mellitus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To compare the direct costs associated with the dexamethasone intravitreal implant (DEX-i) in treatment-naïve and previously treated eyes with diabetic macular edema (DME) in a real clinical setting.
Methods
Retrospective and single-center study conducted in a real clinical scenario. Consecutive DME patients, either naïve or previously treated with vascular endothelial growth factor inhibitors (anti-VEGF), who received treatment with one or more DEX-i between May 2015 and December 2020, and who were followed-up for a minimum of 12 months, were included in the study. The cost analysis was performed from the perspective of the Andalusian Regional Healthcare Service. The primary effectiveness endpoint was the probability of achieving an improvement in best-corrected visual acuity (BCVA) ≥ 15 ETDRS letters after 1 year of treatment. The incremental cost-effectiveness ratio (ICER) of different improvements in BCVA was calculated.
Results
Forty-nine eyes, twenty-eight (57.1%) eyes from the treatment-naïve group and twenty-one (42.9%) from the previously treated group, were included in the analysis. The total cost of one year of treatment was significantly lower in the treatment-naïve eyes than in the previously treated eyes [Hodges-Lehmann median difference: EUR 819.1; 95% confidence interval (CI): EUR 786.9 to EUR 1572.8; p < 0.0001]. The probability of achieving a BCVA improvement of ≥15 letters at month 12 was significantly greater in the treatment-naïve group than in the previously treated group (rate difference: 0.321; 95% CI: 0.066 to 0.709; p = 0.0272). The Cochran–Mantel–Haenszel Odds Ratio of achieving a BCVA improvement of ≥15 letters at month 12 was 3.55 (95% CI: 1.09 to 11.58; p = 0.0309). In terms of ICER, the treatment-naïve group showed cost savings of EUR 7704.2 and EUR 5994.2 for achieving an improvement in BCVA ≥ 15 letters at month 12 and at any of the measured time points, respectively.
Conclusions
DEX-i was found to be more cost-effective in treatment-naïve eyes than in those previously treated with anti-VEGF. Further studies are needed to determine the most cost-effective treatment based on patient profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Puerta del Mar University Hospital, 11009 Cadiz, Spain.
- Puerto Real University Hospital, 11510 Cadiz, Spain.
- Faculty of Medicine and Nursing, University of Córdoba, 14004 Cordoba, Spain.
ORCID-Profile: Eloy Girela-López
Zitieren
APA
Medina-Baena, M., Cejudo-Corbalán, O., Labella-Quesada, F., & Girela-López, E. (2023). Cost-Effectiveness of Dexamethasone Intravitreal Implant in Naïve and Previously Treated Patients with Diabetic Macular Edema. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20085462
Vancouver
Medina-Baena M, Cejudo-Corbalán O, Labella-Quesada F, Girela-López E. Cost-Effectiveness of Dexamethasone Intravitreal Implant in Naïve and Previously Treated Patients with Diabetic Macular Edema. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20085462
BibTeX
@article{MedinaBaena2023,
author = {Medina-Baena, Marta and Cejudo-Corbalán, Olga and Labella-Quesada, Fernando and Girela-López, Eloy},
title = {Cost-Effectiveness of Dexamethasone Intravitreal Implant in Naïve and Previously Treated Patients with Diabetic Macular Edema},
journal = {International Journal of Environmental Research and Public Health},
year = {2023},
doi = {10.3390/ijerph20085462}
}
EUVIMED